Background: Evidence from randomized controlled trials supports the use of triple therapy. Research is required on the effectiveness of quadruple therapy in comparison to this and the relative effectiveness of specific highly active antiretroviral therapy (HAART) combinations.
Introduction
Within 6 years of the events that heralded the onset of the HIV-1 epidemic, 1,2 zidovudine was introduced as a potential treatment. [3] [4] [5] [6] The subsequent elucidation of the crystal structures of the HIV protease 7 and reverse transcriptase 8 led to an escalation of the number of antiretroviral agents available and the development of the two major potent classes of antiretrovirals used today. 9, 10 Currently, there are over 20 agents licensed for treatment and large studies have demonstrated their ability to reduce morbidity and mortality, mainly by preventing opportunistic infections that were common before the advent of combination antiretrovirals in 1996. 11 -15 Many combinations of drugs are possible although owing to resistance profiles, toxicities and interactions between drugs, the actual number of therapeutic options may be limited, particularly in previously treated individuals. 16, 17 This underscores the importance of initiating therapy for HIV-1 infection with the best possible regimen. 18 Such decisions regarding initiation are guided by the patient's HIV-1 RNA level, CD4 cell count, their clinical condition and available data regarding appropriate HAART. 20 -25 A frequently used combination has been zidovudine/ lamivudine and efavirenz (ZDV/3TC/EFV), which is highly effective in clinical trials at suppressing viral replication so that the viral load falls below the detection limit of an assay with a sensitivity of 50 copies/mL. 20, 26 It remains an open question as to whether addition of another nucleoside analogue to the standard regimen would produce a more rapid reduction in initial viral load and more complete suppression of viral replication producing a higher proportion of patients with a negative plasma viral load using an assay with a sensitivity of less than 5 copies/mL. Such changes might be a significant factor in maintaining durable suppression of HIV replication.
We therefore conducted an open-label randomized study to compare the triple highly active antiretroviral therapy (HAART) regimen of zidovudine/lamivudine (Combivir) and efavirenz with the quadruple regimen of zidovudine/lamivudine/abacavir (Trizivir) and efavirenz, in antiretroviral-naive individuals with a high HIV-1 plasma viral load.
Materials and methods
Between March and October 2001, 53 antiretroviral-naive individuals with a plasma viral load >100 000 copies/mL were randomized on a 1:1 basis to receive either the triple drug combination [zidovudine/lamivudine (1 Combivir tablet twice daily) plus efavirenz (600 mg once daily)] or quadruple drug combination [zidovudine/ lamivudine/abacavir (1 Trizivir tablet twice daily) plus efavirenz (600 mg daily)].
Patients were continued on their randomized regimen for the study duration of 48 weeks after which time they received continued therapy. All patients were from the Chelsea and Westminster Hospital, London, provided voluntary, written informed consent and the study received appropriate ethical approval in accordance with the declaration of Helsinki.
CD4 subset analysis was carried out at weeks 4, 8, 12, 16, 24, 36 and 48 using whole blood stained with murine anti-human monoclonal antibodies to CD4 (TetraOne; Beckman Coulter, High Wycombe, UK) and were evaluated on an Epics XL-MCL (Beckman Coulter) flow cytometer. Viral loads in patient plasmas were measured on day 0, 3, 7, 10 and 14 and weeks 4, 8, 12, 16, 24, 36 and 48 using the Quantiplex HIV RNA 3.0 assay with a lower limit of detection of 50 and 5 (both assays were carried out beyond day 7) HIV-1 copies/mL (Roche Diagnostics, Basle, Switzerland).
Analysis
Statistical analyses were carried out in SAS version 8.0 using parametric tests. Where appropriate, data were log 10 transformed to stabilize the variance. MIXED procedure in SAS was used to calculate the difference in averages (DAVG) which represent the timeweighted difference in viral load and CD4 count from baseline to each time point. These have been presented as log viral load slope with 95% confidence intervals. Fold change from baseline was further calculated for viral load and CD4 count for each study time point and these have been presented as percentage change from baseline. On-treatment and two methods of intention-to-treat (ITT) analysis were also carried out, firstly where the last observation (<50 or <5 copies/mL) was carried forward if data were unavailable at the time point and secondly, where any patient whose data were unavailable for any reason was assumed to have failed at the time of analysis. Log rank x 2 test was used to compare time to viral load <5 copies/mL between the two study arms. All P values presented are two-sided.
Fifty patients (25 per arm) were randomized (1:1 randomization) providing 80% power to assess the superiority of the quadruple [ZDV/3TC/abacavir (ABC)/EFV] versus triple (ZDV/3TC/EFV) regimens at the 5% significance level with >0.5 log difference in viral load translated into AAUCMB (area under the curve minus baseline) in plasma RNA using the 5 copy assay. This calculation assumed that 40 patients (20 per arm) would complete 24 weeks of their randomized therapy.
Results
Fifty-three patients were randomized to receive either triple (n = 26) or quadruple (n = 27) HAART. There were no significant differences in baseline characteristics between the two groups. The median viral load in the triple therapy group was 323 593 copies/mL and in the quadruple therapy group, it was 309 030 copies/mL. The median CD4 count was 155 cells/mm For all patients, the log changes in viral load during the 48 week study showed no significant differences between the triple For each study arm, data were analysed for those individuals on-treatment, as an ITT analysis with the last observation carried forward if data were unavailable at the time of analysis, and as an ITT analysis where any patient whose data were unavailable was assumed to have failed at the time of analysis. Using these criteria, comparisons were made of the proportion of individuals in each group who reached an undetectable viral load. Figure 3 shows that similar proportions of individuals in each group reached conventionally undetectable viral loads at each time point in the study. Using ultrasensitive viral load testing, no patients reached undetectable viral load in the quadruple therapy arm by 12 weeks whereas four individuals in the triple therapy arm reached undetectable viral load by this time (Figure 4a and b). Once again these changes were not significant as shown in Table 1 in which the hazard ratio for attaining a viral load of <5 copies/mL was 0.59 (95% CI, 0.26 -1.33, Log rank P = 0.2) for quadruple versus triple therapy.
Three individuals discontinued treatment in the triple therapy arm and nine patients in the quadruple therapy arm (Table 2) . Efavirenz-related mood changes and hepatotoxicity were the most common indications for coming off trial. One patient developed a hypersensitivity reaction to abacavir (an expected proportion). 27 
Discussion
Triple therapy combinations, widely referred to as HAART, lead to a sustained suppression of HIV at levels below the detection limit of commercial viral load assays (<50 copies/mL) in the vast majority of treatment adherent and tolerant individuals. 9, 14 However, a range of different research methodologies have demonstrated that there remains ongoing viral replication in individuals with current viral suppression below commercial assay limits on HAART therapy. 28 -31 Attempts to more completely suppress HIV infection have led to the investigation of combinations of four (or more) antiretrovirals as initial therapy.
A previous large AIDS Clinical Trials Group 384 study compared four-drug regimens containing efavirenz and nelfinavir in combination with either didanosine and stavudine or zidovudine and lamivudine with therapy involving two consecutive threedrug regimens, the first of which contained either efavirenz or nelfinavir. In 980 subjects followed for a median of 2.3 years, there were no significant differences in the duration of successful HIV-1 treatments between a single four-drug regimen and two consecutive three-drug regimens. 32 Interestingly, the same trials group has found that the combination of zidovudine/lamivudine and efavirenz is superior to regimens containing didanosine, stavudine and nelfinavir, as initial therapy in HIV-1 infection. 33 This small randomized study supports these earlier larger trials and demonstrates that over a 48 week study period, this specific triple therapy HAART regimen (ZDV/3TC/EFV) is as effective as a quadruple therapy regimen (ZDV/3TC/ABC/EFV) at suppressing HIV replication and facilitating reconstitution of the immune system. There were no significant differences in viral suppression or CD4 count restoration at any time point and the time to <5 copies/mL HIV-1 RNA was similar in both groups. Subgroup analyses of each arm also failed to show significant differences suggesting the potency of the ZDV/3TC/EFV combination. In addition, more individuals in the quadruple therapy group developed complications resulting in cessation of one or more antiretrovirals.
Systematic reviews have previously demonstrated that the escalation of combinations of antiretroviral drugs up to triple therapy is an effective strategy. 34 -36 Several studies have demonstrated the relative effectiveness of monotherapy versus placebo and double therapy versus monotherapy 37 -41 although future work and trials in progress have often been designed to clarify which triple combination is most effective. 42 There are no randomized data to suggest that the addition of further drugs to a standard triple therapy regimen improves rates of undetectable viral load in HIV-1-infected individuals. A nonrandomized comparison of 30 controls who had not experienced virological failure during 3 years of standard therapy with 10 patients treated with a five-drug regimen showed longer-term suppression of plasma HIV-1 viral load in patients receiving the five-drug combination. 43 However, a three-drug, three-class regimen used in an induction maintenance study could have some advantages. 44 This study does not suggest that a quadruple therapy regimen containing an extra nucleoside analogue confers any benefit over a 48 week study period. Furthermore, as the number of drugs increases, quality of life and safety assume relatively greater importance and in this and other studies the rate of study discontinuation is higher in the arm where additional drugs are administered, whatever treatment is chosen for maximal suppression of viral replication. 23,44 -46 In summary, in persons with high baseline viral load, use of three nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) does not lead to improved virological or immunological efficacy relative to a standard of care two NRTIs plus one NNRTI regimen. For individual patients, the exact balance of risks and benefitsnamely, the chance for long-term viral suppression, the risk of certain side effects, the possibility of induction of drug resistance, and the ability to adhere to a particular regimen-is best addressed by open discussions between care providers and their patients. Three-and four-drug HAART regimens in first-line therapy 
